The FDA’s long-awaited approval earlier this year of the WATCHMAN™ left atrial appendage (LAA) closure device provides an alternative to oral anticoagulation therapy in high-risk patients with nonvalvular atrial fibrillation.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The percutaneous LAA closure device is indicated to reduce the risk of thromboembolism in patients with nonvalvular afib who:
“Since FDA left the indication open to ‘appropriate rationale’ when considering these types of patients, it’s important to define what that is in order to weigh the risks and benefits and select the best candidates,” says Oussama Wazni, MD, Director of the Outpatient Electrophysiology Department and Co-Director of the Ventricular Arrhythmia Center in Cleveland Clinic’s Section of Cardiac Electrophysiology and Pacing.
In this video, Dr. Wazni discusses his clinical criteria for “appropriate rationale”: Patients with a history of bleeding when taking oral anticoagulants, or those whose future risk of bleeding is deemed to be high. He adds: “Implanting the WATCHMAN device in these patients would prevent stroke, while at the same time avoiding the risk of bleeding.”